Open Access and Peer-reviewed
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal News & Announcements


Original Research 
RMJ. 2019; 44(1): 137-140


Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor

Nighat Shaheen, Safia Khalil.

Abstract
Objective: To compare the safety and efficacy of Misoprostol with Oxytocin for management of third stage of labor.
Methodology: This randomized control trial was conducted at Department of Gynecology and Obstetrics, Cantonment General Hospital, Rawalpindi, Pakistan from May to Oct 2015. A total of 212 singleton pregnant women were selected. Women were allocated to either group using simple computer generated randomization table. Group I received 10 U intramuscular Oxytocin while group II received 600ug sublingual Misoprostol. Primary outcome measures were severity of primary postpartum hemorrhage, amount of blood loss and side effects of drugs.
Results: The mean blood loss was 303.50+225.35 in group I and 271.30+206.205 in group II (p=0.035). The average drop in hemoglobin was 0.84+0.78 in group I and 0.81+0.79 in group II (p=0.980). There is no association in two groups with regard to PPH, repeat dose, complications and blood transfusion (p=0.86).
Conclusion: Misoprostol was better than Oxytocin regarding average blood loss for the management of third stage of labor.

Key words: Misoprostol, Oxytocin, Prevention, Postpartum hemorrhage.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Nighat Shaheen
Articles by Safia Khalil
on Google
on Google Scholar
Article Statistics
 Viewed: 1048
Downloaded: 138
Cited: 0


How to Cite this Article
Pubmed Style

Shaheen N, Khalil S. Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor. RMJ. 2019; 44(1): 137-140.


Web Style

Shaheen N, Khalil S. Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor. http://www.rmj.org.pk/?mno=280413 [Access: May 24, 2019].


AMA (American Medical Association) Style

Shaheen N, Khalil S. Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor. RMJ. 2019; 44(1): 137-140.



Vancouver/ICMJE Style

Shaheen N, Khalil S. Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor. RMJ. (2019), [cited May 24, 2019]; 44(1): 137-140.



Harvard Style

Shaheen, N. & Khalil, . S. (2019) Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor. RMJ, 44 (1), 137-140.



Turabian Style

Shaheen, Nighat, and Safia Khalil. 2019. Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor. Rawal Medical Journal, 44 (1), 137-140.



Chicago Style

Shaheen, Nighat, and Safia Khalil. "Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor." Rawal Medical Journal 44 (2019), 137-140.



MLA (The Modern Language Association) Style

Shaheen, Nighat, and Safia Khalil. "Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor." Rawal Medical Journal 44.1 (2019), 137-140. Print.



APA (American Psychological Association) Style

Shaheen, N. & Khalil, . S. (2019) Safety and efficacy of 600 ug sublingual Misoprostol versus 10 U intramuscular Oxytocin for management of third stage of labor. Rawal Medical Journal, 44 (1), 137-140.








AUTHOR LOGIN

REVIEWER LOGIN

Indexed
&
Abstracted


Indexed in WHO Index Medicus IMEMR, Emromedex, Pakmedinet, ExtraMED and Scopus

  Approved by the Higher Education Commission of Pakistan and Pakistan Medical and Dental Council


ABOUT JOURNAL
POLICIES
STATEMENTS

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.

The articles in Rawal Medical Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.